Independent Peptide Research Catalog

A small-molecule NNMT inhibitor that reduces adipocyte size and body weight in obese mice without changing food intake. Marketed as a peptide. It is not one. No human trials exist.

Recombinant fusion protein combining the extracellular domain of activin receptor IIB with human IgG1 Fc. Phase 2 trials in Duchenne muscular dystrophy halted due to bleeding events. Development discontinued.

Vascular-targeting chimeric peptide ablating adipose blood supply; Phase 1 discontinued at MD Anderson 2012-2014 due to renal toxicity concerns.

Copper-binding tripeptide (Ala-His-Lys) developed as a cosmetic ingredient for hair-follicle and skin applications. Less-studied sister compound to GHK-Cu. Cosmetic-grade evidence base only.

Purine nucleoside (Acadesine) that mimics AMP after intracellular phosphorylation, activating AMPK and triggering exercise-like metabolic effects. Endurance mimetic. WADA-banned at all times since 2009. Investigational in cardiovascular and oncology contexts. No FDA approval.

Once-weekly GLP-1 receptor agonist FDA-approved 2014 (Tanzeum, GSK). Recombinant fusion of two GLP-1 copies with human serum albumin. Withdrawn from worldwide market in 2017-2018 by GSK for commercial reasons despite cardiovascular benefit demonstrated in HARMONY Outcomes.

Synthetic tetrapeptide developed by Vladimir Khavinson; telomerase activation claims rest on Khavinson-group rodent studies and small Russian observational reports.

Synthetic Lys-Glu-Asp-Ala tetrapeptide developed as the Khavinson liver and immune Cytogen. Documented chromatin decondensation effects in cell culture.

An endogenous human protein produced in kidneys and brain that declines with age. Mouse overexpression extends lifespan 20-30 percent. Two Phase 1 human trials were initiated in 2025 and 2026. Not approved for any indication.

N-terminally acetylated and C-terminally amidated analog of Semax, the Russian ACTH(4-10) heptapeptide nootropic. Modifications target protease resistance.

Oral non-peptide ghrelin receptor agonist with sustained 24-hour GH elevation; Phase 2 trials completed but no FDA approval after two decades of development.

N-terminal 29-amino-acid fragment of native GHRH; original FDA approval (Geref) withdrawn 2008 for commercial reasons, now compounded for off-label adult use.